Longeveron (LGVN) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update
August 11, 2023 7:30 AM EDTELPIS II Study Exceeds 50% Enrollment Threshold for Phase 2 Trial of Lomecel-BÂ in HLHS
Top Line Results for CLEAR MIND Alzheimers disease Phase 2a Trial Anticipated by October 2023
Company Strengthens Leadership Team and Board of Directors with Distinguished New Additions
Company to Hold Conference Call and Webcast Today, August 11, 2023 at 8am Eastern Time
MIAMI, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative... More
